Randomised phase II study of Cediranib with or without SRC inhibition (Saracatinib) in metastatic clear cell renal cancer (RCC) patients resistant to VEGF targeted therapy

Thomas Powles; Robert Hawkins; Christy Ralph; James Larkin; Robert J Jones; Simon Chowdhury; E Boleti; Kate Fife; A. Bahl; Simon J. Crabb; A. Webb; Omar S. Din; J Dunlop; R Hill; Thomas Geldart; Duncan McLaren; P J  Nathan

Randomised phase II study of Cediranib with or without SRC inhibition (Saracatinib) in metastatic clear cell renal cancer (RCC) patients resistant to VEGF targeted therapy

Thomas Powles, Robert Hawkins, Christy Ralph, James Larkin, Robert J Jones, Simon Chowdhury, E Boleti, Kate Fife, A. Bahl, Simon J. Crabb, A. Webb, Omar S. Din, J Dunlop, R Hill, Thomas Geldart, Duncan McLaren, P J Nathan

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Article number	LBA24A
Journal	Annals of Oncology
Volume	25
Issue number	Suppl_4
Publication status	Published - 1 Sept 2014

Cite this

Powles, T., Hawkins, R., Ralph, C., Larkin, J., Jones, R. J., Chowdhury, S., Boleti, E., Fife, K., Bahl, A., Crabb, S. J., Webb, A., Din, O. S., Dunlop, J., Hill, R., Geldart, T., McLaren, D., & Nathan, P. J. (2014). Randomised phase II study of Cediranib with or without SRC inhibition (Saracatinib) in metastatic clear cell renal cancer (RCC) patients resistant to VEGF targeted therapy. Annals of Oncology, 25(Suppl_4), Article LBA24A.

@article{566c16cbe31c45909b41d4bac53f9837,

title = "Randomised phase II study of Cediranib with or without SRC inhibition (Saracatinib) in metastatic clear cell renal cancer (RCC) patients resistant to VEGF targeted therapy",

author = "Thomas Powles and Robert Hawkins and Christy Ralph and James Larkin and Jones, {Robert J} and Simon Chowdhury and E Boleti and Kate Fife and A. Bahl and Crabb, {Simon J.} and A. Webb and Din, {Omar S.} and J Dunlop and R Hill and Thomas Geldart and Duncan McLaren and Nathan, {P J}",

year = "2014",

month = sep,

day = "1",

language = "English",

volume = "25",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier",

number = "Suppl_4",

}

Powles, T, Hawkins, R, Ralph, C, Larkin, J, Jones, RJ, Chowdhury, S, Boleti, E, Fife, K, Bahl, A, Crabb, SJ, Webb, A, Din, OS, Dunlop, J, Hill, R, Geldart, T, McLaren, D & Nathan, PJ 2014, 'Randomised phase II study of Cediranib with or without SRC inhibition (Saracatinib) in metastatic clear cell renal cancer (RCC) patients resistant to VEGF targeted therapy', Annals of Oncology, vol. 25, no. Suppl_4, LBA24A.

Randomised phase II study of Cediranib with or without SRC inhibition (Saracatinib) in metastatic clear cell renal cancer (RCC) patients resistant to VEGF targeted therapy. / Powles, Thomas; Hawkins, Robert; Ralph, Christy et al.
In: Annals of Oncology, Vol. 25, No. Suppl_4, LBA24A, 01.09.2014.

Research output: Contribution to journal › Meeting abstract › peer-review

TY - JOUR

T1 - Randomised phase II study of Cediranib with or without SRC inhibition (Saracatinib) in metastatic clear cell renal cancer (RCC) patients resistant to VEGF targeted therapy

AU - Powles, Thomas

AU - Hawkins, Robert

AU - Ralph, Christy

AU - Larkin, James

AU - Jones, Robert J

AU - Chowdhury, Simon

AU - Boleti, E

AU - Fife, Kate

AU - Bahl, A.

AU - Crabb, Simon J.

AU - Webb, A.

AU - Din, Omar S.

AU - Dunlop, J

AU - Hill, R

AU - Geldart, Thomas

AU - McLaren, Duncan

AU - Nathan, P J

PY - 2014/9/1

Y1 - 2014/9/1

M3 - Meeting abstract

SN - 0923-7534

VL - 25

JO - Annals of Oncology

JF - Annals of Oncology

IS - Suppl_4

M1 - LBA24A

ER -